Zinzani, P. L. Et Al. 2020. Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL). ESMO Virtual Congress , (ELECTR NETWORK).

Zinzani, P. L., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., ... de Oliveira, J. S. R.(2020). Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL) . ESMO Virtual Congress, ELECTR NETWORK

Zinzani, P. Et Al. "Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)," ESMO Virtual Congress, ELECTR NETWORK, 2020

Zinzani, P. L. Et Al. "Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)." ESMO Virtual Congress , ELECTR NETWORK, 2020

Zinzani, P. L. Et Al. (2020) . "Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)." ESMO Virtual Congress , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={P. L. Zinzani Et Al. }, title={Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)}, congress name={ESMO Virtual Congress}, city={}, country={ELECTR NETWORK}, year={2020}}